help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by TIKKANEN, J. M.
Right arrow Articles by LEMSTRÖM, K. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by TIKKANEN, J. M.
Right arrow Articles by LEMSTRÖM, K. B.

Am. J. Respir. Crit. Care Med., Volume 164, Number 4, August 2001, 672-679

Prevention of Cytomegalovirus Infection-enhanced Experimental Obliterative Bronchiolitis by Antiviral Prophylaxis or Immunosuppression in Rat Tracheal Allografts

JUSSI M. TIKKANEN, ERKKI A. KALLIO, CATHRIEN A. BRUGGEMAN, PETRI K. KOSKINEN, and KARL B. LEMSTRÖM

Cardiopulmonary Research Group of the Transplantation Laboratory, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; and Department of Medical Microbiology, University of Maastricht, Maastricht, The Netherlands

In this study, the prevention of rat cytomegalovirus (RCMV) infection-enhanced experimental obliterative bronchiolitis in rat tracheal allografts was investigated. RCMV infection markedly enhanced cell proliferation and histological changes of obliterative bronchiolitis, a form of chronic rejection after lung transplantation. These alterations were linked to increased interleukin (IL)-2 and tumor necrosis factor-alpha (TNF-alpha ) immunoreactivity, and reduction of IL-10 expression. In recipient rats with acute RCMV infection, prophylaxis with either ganciclovir (DHPG) or hyperimmune serum (HIS) totally prevented RCMV infection-enhanced tracheal occlusion. DHPG treatment initiated during acute RCMV infection also reduced lesion development but markedly less than DHPG prophylaxis. Treatment of acute RCMV infection with HIS alone or in combination with DHPG had no significant effect on tracheal occlusion. Inhibition of the transcription of cytokines by high doses of cyclosporine A significantly reduced RCMV infection-enhanced tracheal obliteration. In rats with chronic RCMV infection, obliterative alterations were prevented by DHPG prophylaxis initiated at the time of transplantation. Prophylaxis either with DHPG or HIS did not affect the amount of infectious RCMV recovered from host salivary glands, nor were there differences seen in RCMV major immediate early DNA expression in tracheal allografts between different antiviral drug regimens. Immunohistochemical analysis of allografts revealed that inhibition of tracheal occlusion by antiviral prophylaxis was associated with a reduction in the number of ED1+ macrophages and cells staining for Th1 cytokines and TNF-alpha , while immune modulation by cyclosporine A up-regulated IL-10 production. In conclusion, the results of the present study suggest that the CMV infection-enhanced chronic rejection develops independently of viral load but requires both immune activation and simultaneous CMV gene expression beyond immediate early genes.

Keywords: obliterative bronchiolitis; cytomegalovirus; chronic rejection; ganciclovir; antisera; cyclosporine A




This article has been cited by other articles:


Home page
 J. Virol.Home page
J. Dumortier, D. N. Streblow, A. V. Moses, J. M. Jacobs, C. N. Kreklywich, D. Camp, R. D. Smith, S. L. Orloff, and J. A. Nelson
Human Cytomegalovirus Secretome Contains Factors That Induce Angiogenesis and Wound Healing
J. Virol., July 1, 2008; 82(13): 6524 - 6535.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. M. Tikkanen, M. Hollmen, A. I. Nykanen, J. Wood, P. K. Koskinen, and K. B. Lemstrom
Role of Platelet-derived Growth Factor and Vascular Endothelial Growth Factor in Obliterative Airway Disease
Am. J. Respir. Crit. Care Med., November 15, 2006; 174(10): 1145 - 1152.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. Krebs, J. M. Tikkanen, A. I. Nykanen, J. Wood, M. Jeltsch, S. Yla-Herttuala, P. K. Koskinen, and K. B. Lemstrom
Dual Role of Vascular Endothelial Growth Factor in Experimental Obliterative Bronchiolitis
Am. J. Respir. Crit. Care Med., June 15, 2005; 171(12): 1421 - 1429.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Tamm, C. L. Aboyoun, P. N. Chhajed, S. Rainer, M. A. Malouf, and A. R. Glanville
Treated Cytomegalovirus Pneumonia Is Not Associated with Bronchiolitis Obliterans Syndrome
Am. J. Respir. Crit. Care Med., November 15, 2004; 170(10): 1120 - 1123.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Boehler and M. Estenne
Post-transplant bronchiolitis obliterans
Eur. Respir. J., December 1, 2003; 22(6): 1007 - 1018.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2001
Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 642 - 662.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2001 American Thoracic Society 		  ATS Clinical Skills Tests